Saltar al contenido


NEOS Cranial LOOP™ Receives FDA Clearance for CustomizedBone™ Use

Kelyniam Global (OTC:KLYG) and Fin-ceramica, Faenza S.p.a., makers of custom cranial implants, announced today that the NEOS Surgery Cranial LOOP™ fixation system has received 510(k) clearance from the FDA for use with Finceramica’s CustomizedBone™ hydroxyapatite cranial implant. The Cranial LOOP™ family of cranial fixation devices is a smart system made of PEEK-OPTIMA™, a biocompatible polymer, for securely fixing bone flaps after craniotomies. With more than 10 years of market experience, Cranial LOOP™ is being used in public and private hospitals in 25 countries worldwide. Cranial LOOP™ was first cleared by the FDA in 2010.  The most recent 510k clearance is for use specifically with Finceramica’s CustomizedBone™ hydroxyapatite cranial implant.

NEOS Cranial LOOP™ Receives FDA Clearance for CustomizedBone™ Use

Kelyniam Global (OTC:KLYG) and Fin-ceramica, Faenza S.p.a., makers of custom cranial implants, announced today that the NEOS Surgery Cranial LOOP™ fixation system has received 510(k) clearance from the FDA for use with Finceramica’s CustomizedBone™ hydroxyapatite cranial implant. The Cranial LOOP™ family of cranial fixation devices is a smart system made of PEEK-OPTIMA™, a biocompatible polymer, for securely fixing bone flaps after craniotomies. With more than 10 years of market experience, Cranial LOOP™ is being used in public and private hospitals in 25 countries worldwide. Cranial LOOP™ was first cleared by the FDA in 2010.  The most recent 510k clearance is for use specifically with Finceramica’s CustomizedBone™ hydroxyapatite cranial implant.

Smartphone misst Glukose im Blut

Forschenden am US-amerikanischen National Institute of Standards and Technology (NIST) gelang die Messung der Glukosekonzentration mit Hilfe eines Mobiltelefons. Das berichtet die DGKL. Dem Bericht zufolge nutzt die Technik den eingebauten Kompass des Smartphones und die Eigenschaften eines intelligenten Hydrogel-Aktuators aus. Hydrogel-Aktuatoren seien Materialien, die auf externe Reize reagieren, indem sie diese in mechanische Bewegung umwandeln. Alles lesen: https://www.dgkl.de/aktuelles/unsere-news/detail?tx_news_pi1%5Bnews%5D=183&cHash=50b6d5b6a19995321b01d1914ea2db55

OptiDrop as leap in single-cell analysis

A new study (DOI: 10.1038/s41378-024-00665-w) published on 12 March, 2024, in the journal Microsystems & Nanoengineering, unveiled an innovative technology that enables multiplexed fluorescence and scatter detection with unprecedented single-cell resolution, using on-chip fiber optics within droplet microfluidic applications. The innovative technology behind the OptiDrop platform marks a significant departure from traditional single-cell analysis methods. By incorporating advanced optical fiber technology directly into microfluidic chips, OptiDrop enables on-chip detection of light scatter and fluorescence from droplets. This novel approach allows for precise analysis of cellular components at a level of detail previously considered unachievable, bypassing the need for complex and costly traditional microscopy and high-speed imaging techniques. The platform has been rigorously tested, demonstrating its ability to perform differential expression analysis of cell surface biomarkers, such as major histocompatibility complex proteins. This not only showcases OptiDrop’s potential for detecting subtle… 

more »OptiDrop as leap in single-cell analysis

CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

ZUG, Switzerland and BOSTON, April 01, 2024 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually. CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

ZUG, Switzerland and BOSTON, April 01, 2024 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually. CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Whole blood rapid test to help with assessment of traumatic brain injury

U.S. Army officials, in partnership with Abbott, announced today that the company’s i-STAT® TBI (Traumatic Brain Injury) cartridge has received clearance from the U.S. Food and Drug Administration to be used with whole blood.  The newly cleared device can run whole blood testing at the patient’s bedside, allowing clinicians to obtain lab quality results for patients suspected of concussion in 15 minutes, according to company officials. Previous tests to help with the assessment of concussion were only cleared for use with plasma or serum, requiring samples to be sent to a laboratory for processing and results.  In addition, patients can be evaluated up to 24 hours after injury, a significant improvement from previously available tests. About the Test A small venous blood sample is applied to the i-STAT TBI test cartridge, which is then inserted into the portable i-STAT Alinity®… 

more »Whole blood rapid test to help with assessment of traumatic brain injury